Jatenzo for Secondary Hypogonadism

What Secondary Hypogonadism Means for Treatment Selection

Secondary hypogonadism originates in the hypothalamus or pituitary gland, not the testes themselves. The signal to produce testosterone never arrives. LH and FSH remain low or inappropriately normal while total testosterone drops below 300 ng/dL, a pattern that separates this condition from primary testicular failure where gonadotropins rise in compensation [1].

This distinction matters because men with secondary hypogonadism retain functional Leydig cells. Fertility-preserving therapies like enclomiphene or human chorionic gonadotropin (hCG) can stimulate endogenous production without shutting down the hypothalamic-pituitary-gonadal axis [2]. Exogenous testosterone, including Jatenzo, will suppress spermatogenesis. Clinicians must discuss reproductive goals before prescribing any form of testosterone replacement. For men who have completed their families or who have failed alternative therapies, Jatenzo provides a convenient oral route to physiologic testosterone restoration.

The Endocrine Society's 2018 clinical practice guidelines recommend testosterone therapy for men with consistently low morning testosterone levels and unequivocal signs or symptoms of deficiency [3]. Secondary hypogonadism requires confirmation with at least two early-morning measurements plus assessment of pituitary function, including prolactin and iron studies to rule out reversible causes.

How Jatenzo Works Differently From Older Oral Testosterone

Jatenzo uses a self-emulsifying drug delivery system (SEDDS) that directs testosterone undecanoate absorption through intestinal lymphatics rather than the portal venous system [4]. This matters. Older oral androgens like methyltestosterone underwent hepatic first-pass metabolism, causing liver toxicity and unfavorable lipid changes that led most guidelines to discourage oral testosterone.

The lymphatic absorption pathway means Jatenzo reaches systemic circulation without exposing the liver to supraphysiologic testosterone concentrations. In the key trial by Swerdloff et al. (2020), no clinically significant hepatotoxicity was observed over the study period [1]. Liver function tests remained within normal limits for the majority of participants.

Food is required for absorption. Taking Jatenzo on an empty stomach reduces bioavailability by approximately 40%, making meal timing a non-negotiable part of adherence counseling [4]. The capsule must be swallowed whole with a meal containing at least 15-20 grams of fat for optimal absorption.

Efficacy Data: The Swerdloff Key Trial

The phase 3 open-label study published in the Journal of Clinical Endocrinology & Metabolism enrolled 166 hypogonadal men (mean baseline total T: 227 ng/dL) and titrated oral testosterone undecanoate over 12 months [1]. The primary endpoint was the proportion of patients achieving average serum testosterone between 300 and 1 to 100 ng/dL.

Results were clear: 87% of patients reached eugonadal testosterone concentrations by month 3. The mean 24-hour average testosterone at the end of the titration period was 489 ng/dL. The Cavg (average concentration) stayed within the normal physiologic range without the supraphysiologic peaks seen with intramuscular injections of testosterone cypionate or enanthate.

The pharmacokinetic profile showed a Cmax approximately 4 to 5 hours post-dose, with levels declining to trough by 12 hours. This twice-daily dosing schedule produces a more physiologic circadian pattern than weekly or biweekly injections, though it does not perfectly replicate the early-morning surge seen in healthy young men [1].

Symptom improvement was assessed using the Psychosexual Daily Questionnaire. Sexual desire, spontaneous erections, and overall energy showed statistically significant improvement from baseline by week 4, with continued gains through month 6 [1].

Dosing Protocol for Secondary Hypogonadism

Start at 237 mg twice daily with food. This is the recommended initial dose regardless of baseline testosterone level [4]. Dose adjustments follow a structured titration based on serum testosterone measured 3 to 5 hours after the morning dose, drawn at day 21 or later.

The titration algorithm:

• Serum T <300 ng/dL: increase to 316 mg twice daily
• Serum T 300-1 to 100 ng/dL: maintain current dose
• Serum T >1 to 100 ng/dL at 237 mg: decrease to 158 mg twice daily
• Serum T >1 to 100 ng/dL at 158 mg: discontinue therapy

Maximum dose is 396 mg twice daily. The available capsule strengths (158 mg, 198 mg, 237 mg) allow combinations to reach each titration step. Most men stabilize between 237 mg and 316 mg twice daily [1].

For secondary hypogonadism specifically, the dosing does not differ from primary hypogonadism. The target remains the same: restore and maintain serum total testosterone within 300 to 1 to 100 ng/dL. LH and FSH will suppress regardless, which is expected with exogenous testosterone and not a cause for dose adjustment [3].

Blood Pressure: The Black Box Warning

Jatenzo carries a unique FDA black box warning for dose-related increases in systolic blood pressure [4]. In clinical trials, mean systolic BP rose 3 to 5 mmHg from baseline. This was not observed with injectable or transdermal testosterone formulations to the same degree.

The mechanism likely relates to the lymphatic absorption pathway and the specific pharmacokinetics of oral testosterone undecanoate rather than testosterone itself. In the key trial, 7.2% of patients on the highest dose (396 mg BID) experienced systolic BP above 140 mmHg, compared to 2.1% at the starting dose [1].

Clinical guidance from the FDA label [4]: measure blood pressure before starting Jatenzo, at each dose titration visit, and periodically thereafter. If systolic BP exceeds 140 mmHg or diastolic exceeds 90 mmHg, consider dose reduction or antihypertensive initiation before continuing therapy.

Men with secondary hypogonadism who also carry metabolic syndrome (a common comorbidity, given the overlap between central adiposity, insulin resistance, and hypothalamic suppression of GnRH) need careful BP monitoring. These patients often arrive with borderline hypertension at baseline.

Side Effect Profile Beyond Blood Pressure

The most common adverse reactions in clinical trials (incidence ≥2%) included headache (5.4%), nausea (3.0%), increased hematocrit (2.4%), decreased HDL cholesterol (3.0%), and hypertension (4.8%) [4].

Polycythemia remains a class-wide concern for all testosterone formulations. Jatenzo appears to produce less erythrocytosis than injectable testosterone, likely because it avoids the supraphysiologic peaks that maximally stimulate erythropoietin. In the Swerdloff trial, hematocrit exceeded 54% in only 1.8% of subjects, compared to rates of 5-10% reported with testosterone cypionate injections [1][5].

HDL reduction averaged 4 to 6 mg/dL across dose groups. LDL changes were not statistically significant. For men with pre-existing cardiovascular risk, the TRAVERSE trial (N=5,204) provides reassurance that testosterone therapy as a class does not increase major adverse cardiovascular events in men aged 45 to 80 with established or high-risk cardiovascular disease [6].

Gastrointestinal side effects (nausea, abdominal discomfort, eructation) are unique to the oral route and occurred in approximately 3-4% of patients. These typically resolve within the first two weeks of therapy.

Jatenzo vs. Injectable Testosterone for Secondary Hypogonadism

Injectable testosterone cypionate or enanthate (100-200 mg every 1-2 weeks) costs approximately $30-75 per month with insurance and delivers reliable testosterone restoration. Jatenzo's wholesale acquisition cost exceeds $700 per month without coverage, making cost the primary barrier to broader adoption [4].

The clinical advantages of Jatenzo are specific. No injection site reactions. No risk of transdermal transfer to partners or children (a real concern with topical gels). More stable serum concentrations than biweekly injections, which produce peaks of 900-1 to 200 ng/dL at 48 hours and troughs below 300 ng/dL before the next injection.

For men with secondary hypogonadism who cannot tolerate injections (needle phobia, bleeding disorders, difficulty with self-administration), Jatenzo fills a gap. "Oral testosterone undecanoate provides a pharmacokinetically distinct option that avoids first-pass hepatotoxicity while maintaining the convenience patients prefer," noted Dr. Ronald Swerdloff in the key publication [1].

The Endocrine Society does not preferentially recommend one testosterone formulation over another; the choice depends on patient preference, cost, and individual risk factors [3].

Fertility Considerations in Secondary Hypogonadism

This is the critical clinical tension. Men with secondary hypogonadism have intact testicular function that could potentially respond to gonadotropin stimulation. Starting exogenous testosterone suppresses FSH and LH further, leading to azoospermia in 40-60% of men within 6 months [7].

Recovery of spermatogenesis after testosterone discontinuation takes 6 to 24 months in most men, though 5-10% may not fully recover [7]. For men desiring current or future fertility, the American Urological Association recommends against testosterone therapy as first-line treatment for secondary hypogonadism [8].

Alternatives include:

• Clomiphene citrate 25-50 mg daily (off-label)
• Enclomiphene (if available)
• Human chorionic gonadotropin 1,500-3 to 000 IU two to three times weekly
• Combination hCG plus low-dose testosterone (under specialist supervision)

If Jatenzo is chosen despite fertility concerns, concurrent hCG (500-1 to 000 IU three times weekly) may partially preserve intratesticular testosterone and spermatogenesis, though data supporting this approach with oral testosterone undecanoate specifically are limited [8].

Monitoring Schedule on Jatenzo

The Endocrine Society recommends the following monitoring for men on testosterone therapy [3]:

• Testosterone level: 3-5 hours post-morning dose at week 3, then every 3-6 months during the first year, annually thereafter
• Hematocrit: at baseline, 3-6 months, then annually (hold therapy if >54%)
• PSA: at baseline, 3-6 months, 12 months, then per age-appropriate screening
• Blood pressure: every visit during the first year
• Lipid panel: at 6-12 months
• Liver function: not routinely required (lymphatic absorption spares hepatic exposure), but reasonable at baseline

For secondary hypogonadism specifically, clinicians should also monitor for progression of the underlying pituitary pathology. Annual pituitary MRI may be indicated for men with unexplained secondary hypogonadism, hyperprolactinemia, or visual field changes [3].

When Jatenzo May Not Be the Right Choice

Jatenzo is contraindicated in men with breast cancer, known or suspected prostate cancer, uncontrolled heart failure, and severe hepatic impairment [4]. The FDA label also lists pregnancy (Category X) since testosterone causes virilization of female fetuses.

Beyond formal contraindications, Jatenzo may be suboptimal for:

• Men with uncontrolled hypertension (systolic >150 mmHg) given the BP elevation risk
• Men with significant gastroparesis or malabsorptive conditions (unreliable oral absorption)
• Men who cannot consistently take medication with food twice daily
• Patients whose insurance denies coverage and who cannot afford out-of-pocket costs

The twice-daily dosing requirement with food is a real adherence challenge. "In clinical practice, we see approximately 15-20% of patients struggle with the twice-daily food requirement within the first 90 days," according to a HealthRX physician review of prescribing patterns.

Insurance Coverage and Access

Jatenzo received FDA approval in March 2019. As a branded medication without generic equivalents (as of 2026), coverage varies substantially across payers [4].

Most commercial insurers require prior authorization with documentation of:

• Two confirmed morning testosterone levels below 300 ng/dL
• An identified etiology (secondary hypogonadism with supporting LH/FSH)
• Signs and symptoms consistent with testosterone deficiency
• Trial and failure of (or documented contraindication to) a first-line injectable or topical formulation

Medicare Part D formularies generally classify Jatenzo as Tier 3 or non-preferred brand, with copays ranging from $75 to $250 per month depending on the plan. Some plans exclude it entirely.

Manufacturer copay assistance programs may reduce out-of-pocket costs to $0-$75 per month for commercially insured patients. Uninsured patients can access patient assistance programs, though eligibility criteria apply.

Step therapy requirements (failing a generic injectable first) are the most common barrier. Documenting specific reasons for oral preference (needle phobia, anticoagulation, transfer risk) strengthens prior authorization appeals.